Nebenwirkungen · Koselugo
Koselugo 5 mg granules in capsule for opening Koselugo 7.5 mg granules in capsule for opening · Abschnitt 4.8 · PDF-Seite 30–31
HOS-145503 · Präparat HOS-099352
Tabulated list of adverse reactions Table 5 presents the adverse reactions identified in the paediatric and adult population with NF1 who have inoperable PN and also in adult patients with multiple tumour types (see footnote to Table 5). The frequency is determined from the paediatric pool (N = 126) and adult patients (N = 137) as defined above. Adverse drug reactions (ADRs) are organised by MedDRA system organ class (SOC). 30 Within each SOC, preferred terms are arranged by decreasing frequency and then by decreasing seriousness. Frequencies of occurrence of adverse reactions are defined as: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000) and not known (cannot be estimated from available data), including isolated reports.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-15T11:39:00Z · SHA-256 a60a44b68868ce8319831dcd6488fab0fc72cf8efb09ef2ef5822453e45d0860 · Passage cbdda37d77df8f5c5fad7b661bda4da490166f41a29b7d66254bf5cc16655bac · Zeichen 4063–4937 im Abschnitt